ClinicalTrials.gg
RecruitingNCT07415837Dystro-miR1Updated Feb 25, 2026

Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies

An interventional study of dosage of blood biomarker miR1 in Duchenne / Becker Muscular Dystrophy, Dystrophia Myotonica 1 and Congenital Myopathies, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Muscular Dystrophy, Duchenne with a site in France — 11 open to participants now, 13 under way, 4 of them phase 3. Muscular Dystrophy, Duchenne · France.

Planned enrollment
21st of 50
104 · median 83
Started
2026
with 4 others
No phase
9 of 66
2 open now
Primary completion
2029-03
later than 6 of 12 live
Registered
64th of 66
by date

Among the 66 studies in Muscular Dystrophy, Duchenne with a site in France, this one is the 21st largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2026, is one of 9 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 64th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

11 of the 66 studies in Muscular Dystrophy, Duchenne with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 2 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Muscular Dystrophy, Duchenne with a site in France, or all of them as a file.
02

Study summary

The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases.

MicroRNAs (miRs) are small messengers that help control how cells grow and stay healthy. Some of these, like miR-1, are specifically found in muscles and the heart. Research shows that levels of miR-1 are often abnormal in people with muscle-wasting conditions, but more information are needed to understand how this relates to the severity of the disease.

The main goal is to compare the blood levels of miR-1 between four different groups at different ages and severities:

  1. Patients with Duchenne or Becker muscular dystrophy (DMD/DMB).
  2. Patients with Myotonic Dystrophy Type 1 (Steinert's disease).
  3. Patients with congenital myopathies.
  4. Healthy volunteers (control group). The main objective is to assess if miR-1 levels can accurately show how a muscular disease is progressing.
03

Conditions studied

  • Duchenne / Becker Muscular Dystrophy
  • Dystrophia Myotonica 1
  • Congenital Myopathies
  • Healthy Participants

Keywords

  • biomarkers
  • neuromuscular diseases
  • micro-RNAs
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Participants must be older than 2 years of age
  • Consent: Participants (or their legal guardians) must provide free and ,. For children, the consent is oral for those under 6 years old and written for those over 6,.
  • Social Security: Every participant must be affiliated with the French social security system.
  • Participants must have a diagnosed neuromuscular pathology : the eligible pathologies are Myotonic Dystrophy Type 1 (DM1 or Steinert's disease), Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (DMB), or congenital myopathies or are healthy participants.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate expressed by the subject or their parental authority.
  • Engaging in intense and unusual physical effort within 10 days before the blood draw.
  • Current use of any treatment with systemic, muscular, or cardiac effects that could interfere with the study's biological results.
  • Subjects or their legal guardians who are under tutelage, curatorship, deprived of liberty, or under judicial protection.
  • Women who are pregnant or breastfeeding.
  • The presence of an additional pathology that, in the judgment of the clinician, could interfere with the biological findings
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    study group

    Diagnostic Test: dosage of blood biomarker miR1

Interventions

  • Diagnostic testdosage of blood biomarker miR1

    Patients and controls will be asked to provide blood samples to evaluate their blood level of miR1 biomarker on a unique time participation.

06

What researchers measure

Primary outcomes

  1. blood expression level of micro-RNA miR-1

    The main goal is to evaluate the interest of miR-1 as a blood biomarker for neuromuscular diseases, specifically muscular dystrophies and congenital myopathies.

    Time frame: at a unique time of enrollment

Secondary outcomes

  1. Demographic Correlations

    The study will analyze the correlation between blood expression levels of miR-1 and the age and sex of the participants

    Time frame: at a unique time of enrollment

  2. Severity correlation

    the study will analyse the correlation between miR-1 levels and the clinical severity of the neuromuscular condition. Severity of Myotonic Dystrophy Type 1 (DM1): miR-1 level relation to the severity of the condition, looking at: * The clinical phenotype (based on the age of disease onset). * The number of CTG nucleotide repeats in the DMPK gene,. * The presence of cardiac involvement,. • Severity of Duchenne and Becker Muscular Dystrophies (DMD/DMB): miR-1 levels based on: * The presence of cardiac involvement, * The loss of ambulation (whether the patient has lost the ability to walk)

    Time frame: at a unique time of enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lopez MA, Si Y, Hu X, Williams V, Qushair F, Carlyle J, Alesce L, Conklin M, Gilbert S, Bamman MM, Alexander MS, King PH. Smad8 Is Increased in Duchenne Muscular Dystrophy and Suppresses miR-1, miR-133a, and miR-133b. Int J Mol Sci. 2022 Jul 7;23(14):7515. doi: 10.3390/ijms23147515. PubMed 35886863 ↗
  • Souidi A, Zmojdzian M, Jagla K. Dissecting Pathogenetic Mechanisms and Therapeutic Strategies in Drosophila Models of Myotonic Dystrophy Type 1. Int J Mol Sci. 2018 Dec 18;19(12):4104. doi: 10.3390/ijms19124104. PubMed 30567354 ↗
  • Vignier N, Amor F, Fogel P, Duvallet A, Poupiot J, Charrier S, Arock M, Montus M, Nelson I, Richard I, Carrier L, Servais L, Voit T, Bonne G, Israeli D. Distinctive serum miRNA profile in mouse models of striated muscular pathologies. PLoS One. 2013;8(2):e55281. doi: 10.1371/journal.pone.0055281. Epub 2013 Feb 13. PubMed 23418438 ↗
  • Matsuzaka Y, Kishi S, Aoki Y, Komaki H, Oya Y, Takeda S, Hashido K. Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy. Environ Health Prev Med. 2014 Nov;19(6):452-8. doi: 10.1007/s12199-014-0405-7. Epub 2014 Aug 24. PubMed 25150707 ↗
  • Zaharieva IT, Calissano M, Scoto M, Preston M, Cirak S, Feng L, Collins J, Kole R, Guglieri M, Straub V, Bushby K, Ferlini A, Morgan JE, Muntoni F. Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy. PLoS One. 2013 Nov 25;8(11):e80263. doi: 10.1371/journal.pone.0080263. eCollection 2013. PubMed 24282529 ↗
  • Kirby TJ, Chaillou T, McCarthy JJ. The role of microRNAs in skeletal muscle health and disease. Front Biosci (Landmark Ed). 2015 Jan 1;20(1):37-77. doi: 10.2741/4298. PubMed 25553440 ↗
  • Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014 Dec 19;14:135. doi: 10.1186/1471-2288-14-135. PubMed 25524443 ↗
  • Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009 Oct;10(10):704-14. doi: 10.1038/nrg2634. PubMed 19763153 ↗
  • Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002 Apr 30;12(9):735-9. doi: 10.1016/s0960-9822(02)00809-6. PubMed 12007417 ↗
  • Rau F, Freyermuth F, Fugier C, Villemin JP, Fischer MC, Jost B, Dembele D, Gourdon G, Nicole A, Duboc D, Wahbi K, Day JW, Fujimura H, Takahashi MP, Auboeuf D, Dreumont N, Furling D, Charlet-Berguerand N. Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nat Struct Mol Biol. 2011 Jun 19;18(7):840-5. doi: 10.1038/nsmb.2067. PubMed 21685920 ↗
  • Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005 Sep;4(9):1179-84. doi: 10.4161/cc.4.9.2032. Epub 2005 Sep 15. PubMed 16096373 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2029, 37 months after the start.

Of 45 non-industry interventional studies with no phase under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 37 months is above that.

Counting every sponsor, half of 47 studies reached it within 20 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 17, 2026
StartActual
Feb 11, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07415837
Collaborators
Université d'Auvergne
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Feb 11, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Feb 25, 2026

Study contacts

Lise Laclautre, PhD
Contact
promo_interne_drci@chu-clermontferrand.fr
+33473750750
Catherine Sarret, MD, PhD, Prof
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion